Madison, WI, USA, July 12, 2011 / B3C newswire / - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Caliper Life Sciences , Inc. (NASDAQ: CALP) today announced a co-marketing agreement for the development and optimization of automated protocols for the NimbleGen SeqCap EZ Library solution-based capture method for Caliper’s Sciclone NGS Workstation. The collaboration aims to simplify high throughput targeted resequencing workflows by developing automated methods for sequencing library preparation and enrichment of target regions, quantification, and quality control. The automated methods will enable biomedical researchers worldwide to analyze large cohorts to discover and confirm genetic variants that contribute to human disease.
“Roche NimbleGen is committed to providing the research community with innovative and enabling solutions for targeted resequencing,” said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc. “The continued exponential growth of sequencing throughput and the volume of samples to be analyzed has shifted the bottleneck to sample preparation and process control. By combining our solutions with Caliper’s NGS workstation, the bottlenecks are eliminated, creating the capacity to analyze large cohorts and optimize research efforts.”
“Caliper’s Sciclone NGS Workstation significantly accelerates high throughput sequencing sample preparation and enrichment for numerous sequencing chemistries and workflows,” said Kevin Hrusovsky, President and CEO of Caliper Life Sciences. “Together Caliper and Roche NimbleGen are developing targeted sequencing applications that enable studies that analyze variants across large populations to detect and better understand the causal agents of disease."
For further information about Roche please contact:
Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected].
Roche NimbleGen
Kary Staples
Phone: +1 608 218 7623
Email: [email protected].